|
Cyplasin™ investor information Cyplasin Biomedical Ltd. is publicly traded under the symbol OTCBB: CYPL. Cyplasin is headquartered in Edmonton, Alberta, Canada. The Company is a product development company focused on developing therapeutic products for use in cancer.
The first product to be developed will be Cyplasin-SC™ for use in skin cancer and melanoma applications. The Company will use multiple partners on a global outsourcing basis to fast track cyplasin development thus creating a rapid and efficient pathway to commercialization. Cyplasin-SC may either be formulated for administered via microinjection close to the skin tumor or intradermally (under the skin) or intravenously (I.V) into the bloodstream. Please contact us to request more information about Cyplasin-SC. Auditors Dale Matheson Carr-Hilton Labonte LLP Legal Counsel Bill Macdonald Stock Transfer Agent Pacific Stock Transfer Industry Sector Information 2002 NAICS Stock Information OTC Symbol OTCBB:CYPL Shares issued and outstanding: 38,584,000 Investor Relations Contact Cyplasin Biomedical Ltd. Phone: Fax: Email: Caution Regarding Forward-Looking Statements This Web site contains historical information as well as forward-looking statements that are based upon our estimates and anticipation of future events that are subject to certain risks and uncertainties that could cause actual results to vary materially from the expected results described in the forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "hopeful," "intend," "may," "optimistic," "preliminary," "project," "should," "will," and similar expressions are intended to identify these forward-looking statements. There are numerous important factors that could cause our actual results to differ materially from those in the forward-looking statements. Thus, sentences and phrases that we use to convey our view of future events and trends are expressly designated as Forward-Looking Statements as are sections of this web site or associated news release which clearly are identified as giving our outlook on future business. These forward-looking statements are subject to significant risks, assumptions and uncertainties, including, among other things, the following important factors that could affect the actual outcome of future events:
Please see our SEC filings for detailed risk analysis We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made, and wish to advise readers that the factors listed above could affect our financial performance and could cause actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. We do not undertake and specifically decline any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. |
The
Company is developing a recombinant protein called Cyplasin™ (pronounced
'sigh play sin') which was originally isolated from a marine organism
called the sea hare (Aplysia punctata). Cyplasin has demonstrated high
cytotoxicity against various types of cancer cells while showing no
cytotoxic effect against non cancer or healthy cells. This selective
toxicity/safety profile potentially makes the cyplasin protein an excellent
therapeutic candidate for treating a variety of cancers.|
Cyplasin is a public company registered on the OTC bulletin board under the trading symbol CYPL, and the Frankfurt Exchange under the trading symbol XYIA. |